Quince Therapeutics

$QNCX Investors: Today, we announced the successful settlement of our outstanding obligations under the company’s loan from the European Investment Bank. Read more here: ir.quincetx.com/news-releases/…

$QNCX Investors: We announced the engagement of LifeSci Capital to serve as our exclusive financial advisor to assist in a restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Read more here: ir.quincetx.com/news-releases/…

$QNCX Investors: We announced topline results from our pivotal Phase 3 NEAT clinical trial of eDSP in Ataxia-Telangiectasia. Read more here: ir.quincetx.com/news-releases/…

$QNCX Investors: We are pleased to participate at the British Paediatric Neurology Association 2026 Annual Meeting with a poster presentation highlighting previously published safety data from the long-term treatment of children with A-T. Learn more here: ir.quincetx.com/news-releases/…

Listen in to a recent conversation Quince’s CEO & CMO Dr. Dirk Thye had with Max Brennan at The BioHub Podcast. Check it out here: youtu.be/Wdyl33epIZs?si… $QNCX #biotech #raredisease #innovation

$QNCX Investors: Our CEO & CMO Dr. Dirk Thye recently caught up with reporter Dr. Adil Ali for an interview produced by Onyx News, published in Fortune. Check it out here: onyxnewsroom.com/how-quince-pla…

$QNCX Investors: Read the latest profile story on Quince Therapeutics out today on Seeking Alpha: seekingalpha.com/article/485879… #biotech #raredisease #innovation

$QNCX Investors: Listen in tomorrow January 7th at 10 a.m. ET as Citizens hosts a call with expert neurologist Dr. Susan Perlman (UCLA) ahead of pivotal Phase 3 NEAT data to discuss the unmet need in A-T and the opportunity for eDSP. Register here: netroadshow.com/events/login/L…

$QNCX Investors: We are pleased to announce the last patient last visit in the pivotal Phase 3 NEAT clinical trial of our lead asset, eDSP, in patients with A-T. We expect to report topline results from this study in the middle of Q1 2026. Read more here: ir.quincetx.com/news-releases/…

$QNCX Publication Alert: We’re pleased to announce the publication of a summary of early-stage clinical studies of eDSP in pulmonary and inflammatory bowel disorders in the scientific journal Frontiers in Drug Delivery. Read more here: ir.quincetx.com/news-releases/…

$QNCX Investors: Don’t miss the opportunity to hear our CEO & CMO Dirk Thye’s fireside chat at today’s Piper Sandler 37th Annual Healthcare Conference beginning at 10:30 a.m. Eastern Time. Listen in here: ir.quincetx.com/events/event-d…

$QNCX Investors: Listen to Quince President Charles Ryan, J.D., Ph.D., outline the attractive commercial opportunity and launch preparedness planning for our lead asset eDSP as we move toward reporting topline results in the first quarter of 2026. #RareDisease #Biotech

$QNCX Investors: Looking forward to participating at the Piper Sandler 37th Annual Healthcare Conference, Oppenheimer Movers in Rare Disease Summit, and Lunch with LifeSci Fireside Chat in December 2025. Read about the events here: ir.quincetx.com/news-releases/…

$QNCX Investors: Listen to Quince Vice President of Nonclinical Development, Caralee Schaefer, Ph.D., describe novel insights from our landmark RNA sequencing dataset from the largest clinical trial of patients with Ataxia-Telangiectasia! #AtaxiaTelangiectasia #RareDisease

$QNCX Investors: Listen to Quince CEO & CMO Dirk Thye, M.D., describe how our pivotal Phase NEAT clinical trial is designed to maximize confidence and minimize risk as the company moves toward reporting topline results in the first quarter of 2026. #AtaxiaTelangiectasia

$QNCX Investors: Today, Quince provided a business update detailing our latest clinical and corporate activities and reported third quarter 2025 results. Read more in the news release here: ir.quincetx.com/news-releases/…

$QNCX Investors: We are pleased to announce the positive outcome from a recent independent data and safety monitoring board review for eDSP in our pivotal Phase 3 NEAT clinical trial in A-T – with no safety concerns identified by the iDSMB. Read more here: ir.quincetx.com/news-releases/…

ICYMI – Now’s the perfect time to watch the replay of our recent 2025 Virtual Investor Day and hear why we’re so excited about our pivotal Phase 3 topline results expected in Q1 2026. Watch here: ir.quincetx.com/events/event-d… $QNCX #raredisease #innovation

$QNCX Investors: Looking forward to attending the 2025 Maxim Growth Summit this week where our CEO & CMO Dirk Thye, M.D., will participate in the Unlocking Value in Late-Stage/Commercial Rare Disease panel discussion.

$QNCX Investors: We are pleased to participate at the 54th Child Neurology Society Annual Meeting with a poster and publication describing age-related walking capacity loss in patients with A-T compared to ICARS AND RmICARS measures. Learn more here: ir.quincetx.com/news-releases/…